| 1 |
Cancer treatment and survivorship statistics, 2016  |
미소장 |
| 2 |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.  |
미소장 |
| 3 |
EGFR T790M resistance mutation in non small-cell lung carcinoma  |
미소장 |
| 4 |
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.  |
미소장 |
| 5 |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins  |
미소장 |
| 6 |
MicroRNA expression and function in cancer.  |
미소장 |
| 7 |
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.  |
미소장 |
| 8 |
Plasma MiR-21: A Potential Diagnostic Marker of Colorectal Cancer  |
미소장 |
| 9 |
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.  |
미소장 |
| 10 |
microRNA expression profile in a large series of bladder tumors: Identification of a 3‐miRNA signature associated with aggressiveness of muscle‐invasive bladder cancer  |
미소장 |
| 11 |
Up-regulation ofis a potent prognostic marker for lung adenocarcinoma of female non-smokers  |
미소장 |
| 12 |
Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation  |
미소장 |
| 13 |
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124  |
미소장 |
| 14 |
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.  |
미소장 |
| 15 |
Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA. org resource: targets and expression. Nucleic Acids Res 2008; 36: D149-53. |
미소장 |
| 16 |
Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles  |
미소장 |
| 17 |
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.  |
미소장 |
| 18 |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.  |
미소장 |
| 19 |
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.  |
미소장 |
| 20 |
The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP  |
미소장 |
| 21 |
The quest to overcome resistance to EGFR-targeted therapies in cancer.  |
미소장 |
| 22 |
Acquired resistance to TKIs in solid tumours: learning from lung cancer.  |
미소장 |
| 23 |
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.  |
미소장 |
| 24 |
Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.  |
미소장 |
| 25 |
microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers.  |
미소장 |
| 26 |
MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis.  |
미소장 |
| 27 |
Role of MicroRNA-1 in Human Cancer and Its Therapeutic Potentials  |
미소장 |
| 28 |
miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1.  |
미소장 |
| 29 |
miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.  |
미소장 |
| 30 |
Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer  |
미소장 |
| 31 |
Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer  |
미소장 |
| 32 |
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.  |
미소장 |
| 33 |
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.  |
미소장 |
| 34 |
EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.  |
미소장 |
| 35 |
Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation  |
미소장 |
| 36 |
MicroRNA Expression Aids the Preoperative Diagnosis of Pancreatic Ductal Adenocarcinoma  |
미소장 |
| 37 |
Clinical Potential of MicroRNAs in Pancreatic Ductal Adenocarcinoma  |
미소장 |
| 38 |
MicroRNA‐196: critical roles and clinical applications in development and cancer  |
미소장 |
| 39 |
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.  |
미소장 |
| 40 |
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.  |
미소장 |
| 41 |
Up-regulation of miR-124 inhibits invasion and proliferation of prostate cancer cells through mediating JAK-STAT3 signaling pathway.  |
미소장 |
| 42 |
MiR-124 inhibits the growth of glioblastoma through the downregulation of SOS1.  |
미소장 |
| 43 |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis.  |
미소장 |
| 44 |
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.  |
미소장 |